Literature DB >> 25599679

Kawasaki disease and its treatment - an update.

A K M Mamunur Rashid, Sikder Mohammad Kamal, Md Ashrafuzzaman, Khan Golam Mustafa1.   

Abstract

AIM: The aim of this review is to update the knowledge about the Kawasaki disease (KD) which includes the way of early detection and latest treatment plan for the disease.
METHOD: A number of literatures were reviewed and latest information about the etiology, diagnosis, laboratory investigation, treatment and outcome of the disease was collected and depicted in the review article. RESULT: Kawasaki disease is a multisystem vasculitis mainly affecting medium sized blood vessels. It is the second most common cause of vasculitis after Henoch Scholein Purpura (HSP) in children. Etiology of the disease is still unknown. Auto-immunity with genetic influence is thought to associate with the disease. Many physicians are ignorant of the disease. The pediatrician must be aware of the disease and suspect this condition in less than 5 year old children presenting with more than 5 days fever. the number of methods on the basis of criteria is set for the diagnosis of the disease. Latest treatment plan is set up for the disease which reduces the morbidity and mortality to a great extent.
CONCLUSION: Physicians must have consciousness and comprehensive knowledge for the early suspicion of this disease. Any child presenting with fever for more than 5 days should not be ignored and other criteria of KD have to be evaluated by the physician. Early diagnosis and updated treatment are imperative for the prevention of morbidity and mortality for the disease.

Entities:  

Mesh:

Year:  2014        PMID: 25599679     DOI: 10.2174/1573397111666150120144457

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  1 in total

1.  Clinical Outcomes of Low-Dose Methotrexate Therapy as a Second-Line Drug for Intravenous Immunoglobulin-Resistant Kawasaki Disease.

Authors:  Hyejin Jang; Kyu Yeun Kim; Dong Soo Kim
Journal:  Yonsei Med J       Date:  2018-01       Impact factor: 2.759

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.